To cite this paper use one of the standards below:
Please log in to watch the video
Log inINTRODUCTION AND OBJECTIVES: It is expected that colorectal cancer (CCR) will be the second and third most frequent cancer among women and men in Brazil in the 2020-22 triennium. In such a scenario, it is of utmost importance to understand the molecular biology of CCR in order to improve its prevention and treatment. More than 75% of CCR tumors harbor mutations in the TP53 gene. In response to genotoxic stressors, TP53 encodes a tumor suppressor protein with a classic role of arresting the cell cycle or inducing programmed cell death to limit the propagation of undesired genome mutations. Recently, many studies have found associations of TP53 mutations with the dynamics of the appearance and resistance of tumor stem cells. In CCR, both normal adult and cancer stem cells have been identified and tracked through the leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) biomarker. Therefore, we aimed to investigate a putative role of TP53 in the appearance of LGR5 positive CCR cancer stem cells. MATERIAL AND METHODS: AOM/DSS is the most used inflammation-driven CCR inducing model in mice, which resembles the human inflammatory CCR. TP53 wild-type (WT), heterozygous (HET) and knock-out (KO) mice were subjected to the AOM/DSS model. CCR tumor samples were collected, snap-frozen and colorectal samples were processed for further hematoxylin-eosin (HE) staining, immunohistochemistry (IHC) and Western Blot (WB) analysis. RESULTS AND CONCLUSION: The KO group lost more body weight in response to the three cycles of the colitis agent dextran sulfate sodium (DSS), as well as more frequent episodes of diarrhea or bleeding in stool, indicating more aggressive colitis. Colonoscopies at the end of the AOM/DSS protocol showed an increased number of tumors in the KO group at the same moment WT and HET had few small or absence of visible tumors, leading to a delayed euthanasia in the WT and HET groups. At euthanasia, intestines were dissected and visible tumor size and number of tumors were higher in the KO group. Western blot analysis of non-tumoral colorectal tissue showed no difference in LGR5 expression in relation to TP53 genotypes, although it indicates a slight trend of decrease in KO group. HE staining showed the presence of well-differentiated in situ and invasive adenocarcinomas in mice. Most tumors presented a polypoid morphology, but we are also evaluating the frequency of the serrated tumors among groups. IHC analysis indicates increased immunostaining of LGR5 in tumors of the KO group, which seems to confirm WB analysis of tumor samples. LGR5 expression also seems to indicate a field effect in colon tissue since its expression might be increased in the adjacent and distant non-tumoral tissue surrounding cancer tissue. Our results, so far, indicate that LGR5 is upregulated in KO tissues, which confirms the importance of TP53 to the regulation of stemness in CCR cancers and to the cancer stem cells.
Anderson Junger Teodoro
O autor acha este comportamento específico do câncer de colon ou esta regulação da TP53 pode ocorrer em outros tipos de câncer? Pq?
Murilo Rocha
Olá João. Parabéns a você e aos co-autores por esses resultados bem interessantes. Queria perguntar sua opinião sobre a possível variação inversa de LGR5 entre tecido não-tumoral e tumoral nos animais WT ou KO. Existem alguns indícios que o LGR5 esteja associado de forma geral tanto com células tronco do cólon normal ou tumoral. Como você explicaria a redução de LGR5 nos tumores WT em comparação com o não tumoral, enquanto nos animais KO há um aumento. Acredita que outras vias estejam relacionadas?
Mariana Emerenciano
Boa tarde, João Marcos!
Parabéns pelo trabalho e pelo vídeo apresentando seus resultados.
Se seus dados vierem a comprovar que TP53 contribui para o 'surgimento' de células tonco tumorais LGR5 positivas, qual seria uma possibilidade terapêutica para estes pacientes?
Este potencial papel de TP53 como indutor para o aparecimento/resistência de células tronco tumorais já foi descrito em outros tipos de cânceres? Se sim, quais?
Muito obrigada e sucesso com a finalização do trabalho.
Abraços
Mariana Emerenciano
https://www.inca.gov.br/pesquisa/pesquisa-clinica/medicina-molecular/estudo-molecular-do-cancer
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper